agilon health(US:AGL) Globenewswire·2026-01-02 20:33Core Viewpoint - A securities fraud lawsuit has been filed against agilon health, inc. following a significant drop in its stock price due to the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Shares of agilon health, Inc. fell more than 25% in after-hours trading on August 4, 2025, after the announcement of CEO Steven Sell's immediate resignation and the withdrawal of the full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Allegations in the Lawsuit - The complaint alleges that agilon recklessly issued guidance for 2025 that they knew or should have known was unattainable due to material industry headwinds [3]. - It is claimed that agilon materially overstated the immediate positive financial impact from strategic actions taken to reduce risk, leading to materially false and/or misleading statements about the company's business and prospects [3]. Group 3: Investor Information - Investors who purchased agilon health, inc. common stock between February 26, 2025, and August 4, 2025, and have experienced a loss may be eligible to participate in the lawsuit [4]. - The deadline to seek appointment as lead plaintiff is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about agilon health, inc. are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].